(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566771

カペシタビン市場：適応症別、薬剤タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Capecitabine Market By Indication (Colorectal Cancer, Breast Cancer, Others) , By Drug Type (Branded, Generic) By End User (Hospitals, Homecare, Specialty Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
カペシタビン市場：適応症別、薬剤タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のカペシタビン市場は2023年に4億米ドルと評価され、2024～2033年にかけてCAGR 5％で成長し、2033年には7億米ドルに達すると予測されています。

カペシタビンは、乳がん、結腸がん、直腸がんなど、さまざまながんの治療に用いられる経口化学療法薬です。カペシタビンは代謝拮抗薬として知られる薬剤の一群に属し、がん細胞の増殖と転移を阻害することで効果を発揮します。カペシタビンはプロドラッグであり、体内で活性型の5-フルオロウラシル（5-FU）に変換されます。いったん変換されると、5-FUはがん細胞のDNAとRNAの合成を阻害し、死滅に導く。従来の化学療法剤が静脈内投与であるのに対し、カペシタビンは経口投与で、通常は錠剤の形で服用します。このため患者にとって利便性が高く、多くの場合外来での治療が可能です。

カペシタビン市場の成長を牽引しているのは、がんの有病率の上昇です。世界のがん患者数の増加に伴い、効果的な治療オプションに対する需要が急増しています。さらに、高齢者人口の増加がカペシタビン市場の重要な促進要因として浮上しています。高齢になると、遺伝子の突然変異の蓄積、免疫システムの弱体化、生涯にわたる発がん物質への長期暴露などの要因により、がんを発症しやすくなります。このような高齢化社会への人口動態の変化は、高齢者のがん診断の有病率の上昇につながり、カペシタビンのような効果的ながん治療に対する需要の増大を生み出しています。

しかし、貧血、胸部不快感、嘔吐、血液凝固障害など、カペシタビンに関連する副作用が市場の成長を妨げています。一方、製品の革新、上市、市場の多様化は、市場参入企業に有利な機会を記載しています。例えば、2022年12月、Shilpa Medicare Ltd.は、90秒以内の高速分散という新技術を搭載したカペシタビン1,000MG分散錠の発売を発表しました。同製品は、必要な科学的証明と生物学的同等性比較試験によって裏付けられ、インドにおける医療製品の安全性、有効性、品質を保証する責任を負うインドの国家規制当局（NRA）である中央医薬品標準管理機構（CDSCO）の承認を得ています。本製品は大腸がんと転移性乳がんの治療に使用されます。

セグメント概要

世界のカペシタビン市場は、適応症、薬剤タイプ、エンドユーザー、地域に区分されます。適応症別では、大腸がん、乳がん、その他に分けられます。薬剤タイプ別では、ブランド薬とジェネリック医薬品に分類されます。エンドユーザー別では、病院、在宅医療、専門センター、その他に分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

適応症別では、乳がんセグメントが2023年の市場最大株主でした。

薬剤タイプ別では、ブランドセグメントが2023年に最も高い市場シェアを占めました。

エンドユーザー別では、病院セグメントが2023年に最大シェアを占めました。

地域別では、北米が2023年のカペシタビン市場を独占しました。

競合シナリオ

本レポートはカスタマイズが可能です。

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 カペシタビン市場：適応症別

  • 市場概要
  • 大腸がん
  • 乳がん
  • その他

第5章 カペシタビン市場：薬剤タイプ別

  • 市場概要
  • ブランド
  • ジェネリック

第6章 カペシタビン市場：エンドユーザー別

  • 市場概要
  • 病院
  • 在宅医療
  • 専門クリニック
  • その他

第7章 カペシタビン市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国のカペシタビン市場
    • カナダのカペシタビン市場
    • メキシコのカペシタビン市場
  • 欧州
    • 主要市場の動向と機会
    • ドイツのカペシタビン市場
    • フランスのカペシタビン市場
    • 英国のカペシタビン市場
    • イタリアのカペシタビン市場
    • スペインのカペシタビン市場
    • その他の欧州のカペシタビン市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本のカペシタビン市場
    • 中国のカペシタビン市場
    • オーストラリアのカペシタビン市場
    • インドのカペシタビン市場
    • 韓国のカペシタビン市場
    • その他のアジア太平洋のカペシタビン市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルのカペシタビン市場
    • サウジアラビアのカペシタビン市場
    • 南アフリカのカペシタビン市場
    • その他のラテンアメリカ・中東・アフリカのカペシタビン市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Novartis AG
  • Bayer AG
  • Eli Lilly And Company.
  • Merck And Co., Inc.
目次
Product Code: A03017

The global capecitabine market was valued at $0.4 billion in 2023, and is projected to reach $0.7 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

Capecitabine is an oral chemotherapy medication used in the treatment of various cancers, including breast, colon, and rectal cancers. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and spread of cancer cells. Capecitabine is a prodrug, meaning it is converted into its active form, 5-fluorouracil (5-FU), in the body. Once converted, 5-FU inhibits the synthesis of DNA and RNA in cancer cells, leading to their death. Traditional chemotherapy drugs administered intravenously, whereas capecitabine is taken orally, usually in the form of tablets. This offers convenience to patients and allows for outpatient treatment in many cases.

The growth of the capecitabine market is driven by rise in the prevalence of cancer. With the growing number of cancer patients globally, there is surge in demand for the effective treatment option. Moreover, rise in geriatric population has emerged as a significant driver of the capecitabine market. As individuals age, they become more susceptible to developing cancer due to factors such as accumulated genetic mutations, weakened immune systems, and prolonged exposure to carcinogens over their lifetime. This demographic shift toward an aging population has led to a higher prevalence of cancer diagnoses among older adults, creating a greater demand for effective cancer treatments such as capecitabine.

However, adverse effects related to capecitabine, such as anemia, chest discomfort, vomiting, and blood clotting disorders, hamper the growth of the market. On the other hand, product innovation, launches, and diversification present lucrative opportunities for the market players. For instance, in December 2022, Shilpa Medicare Ltd. announced the launch of the Capecitabine 1000 MG dispersible tablet with novel technology of faster dispersion within 90 seconds. The product is supported by required scientific proof and comparative bioequivalence studies and is approved by Central Drugs Standard Control Organisation (CDSCO) -the National Regulatory Authority (NRA) of India, responsible for ensuring the safety, efficacy, and quality of medical products in the country. The product is used for treatment of colorectal and metastatic breast cancer.

Segmentation Overview

The global capecitabine market is segmented into indication, drug type, end user, and region. By indication, the market is divided into colorectal cancer, breast cancer, and others. Depending on drug type, it is categorized into branded and generic. According to end user, the market is classified into hospitals, homecare, specialty centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By indication, the breast cancer segment was the largest shareholder in the market in 2023.

Depending on drug type, the branded segment held the highest market share in 2023.

According to end user, the hospitals segment accounted for the maximum share of the market in 2023.

Region wise, North America dominated the capecitabine market in 2023.

Competitive Scenario

The major players operating in the capecitabine market include F. Hoffmann-La Roche Ltd., Mylan N.V, Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Novartis AG, Bayer AG, Eli Lilly and Company, and Merck & Co., Inc. Other players in the market include GlaxoSmithKline Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, and Alkem Labs Ltd. These players have adopted several strategies, including product diversification & innovation, mergers & acquisitions, and collaborations to maintain their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Indication

  • Colorectal Cancer
  • Breast Cancer
  • Others

By Drug Type

  • Branded
  • Generic

By End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • F. Hoffmann-La Roche Ltd.
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Novartis AG
    • Bayer AG
    • Eli Lilly and Company.
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CAPECITABINE MARKET, BY INDICATION

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Indication
  • 4.2. Colorectal Cancer
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Breast Cancer
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: CAPECITABINE MARKET, BY DRUG TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Drug Type
  • 5.2. Branded
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Generic
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: CAPECITABINE MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Homecare
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Specialty Clinics
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: CAPECITABINE MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Indication
    • 7.2.3. Market Size and Forecast, By Drug Type
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Capecitabine Market
      • 7.2.6.1. Market Size and Forecast, By Indication
      • 7.2.6.2. Market Size and Forecast, By Drug Type
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Capecitabine Market
      • 7.2.7.1. Market Size and Forecast, By Indication
      • 7.2.7.2. Market Size and Forecast, By Drug Type
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Capecitabine Market
      • 7.2.8.1. Market Size and Forecast, By Indication
      • 7.2.8.2. Market Size and Forecast, By Drug Type
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Indication
    • 7.3.3. Market Size and Forecast, By Drug Type
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Capecitabine Market
      • 7.3.6.1. Market Size and Forecast, By Indication
      • 7.3.6.2. Market Size and Forecast, By Drug Type
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Capecitabine Market
      • 7.3.7.1. Market Size and Forecast, By Indication
      • 7.3.7.2. Market Size and Forecast, By Drug Type
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Capecitabine Market
      • 7.3.8.1. Market Size and Forecast, By Indication
      • 7.3.8.2. Market Size and Forecast, By Drug Type
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Capecitabine Market
      • 7.3.9.1. Market Size and Forecast, By Indication
      • 7.3.9.2. Market Size and Forecast, By Drug Type
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Capecitabine Market
      • 7.3.10.1. Market Size and Forecast, By Indication
      • 7.3.10.2. Market Size and Forecast, By Drug Type
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Capecitabine Market
      • 7.3.11.1. Market Size and Forecast, By Indication
      • 7.3.11.2. Market Size and Forecast, By Drug Type
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Indication
    • 7.4.3. Market Size and Forecast, By Drug Type
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Capecitabine Market
      • 7.4.6.1. Market Size and Forecast, By Indication
      • 7.4.6.2. Market Size and Forecast, By Drug Type
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Capecitabine Market
      • 7.4.7.1. Market Size and Forecast, By Indication
      • 7.4.7.2. Market Size and Forecast, By Drug Type
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. Australia Capecitabine Market
      • 7.4.8.1. Market Size and Forecast, By Indication
      • 7.4.8.2. Market Size and Forecast, By Drug Type
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. India Capecitabine Market
      • 7.4.9.1. Market Size and Forecast, By Indication
      • 7.4.9.2. Market Size and Forecast, By Drug Type
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Capecitabine Market
      • 7.4.10.1. Market Size and Forecast, By Indication
      • 7.4.10.2. Market Size and Forecast, By Drug Type
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Capecitabine Market
      • 7.4.11.1. Market Size and Forecast, By Indication
      • 7.4.11.2. Market Size and Forecast, By Drug Type
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Indication
    • 7.5.3. Market Size and Forecast, By Drug Type
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Capecitabine Market
      • 7.5.6.1. Market Size and Forecast, By Indication
      • 7.5.6.2. Market Size and Forecast, By Drug Type
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Capecitabine Market
      • 7.5.7.1. Market Size and Forecast, By Indication
      • 7.5.7.2. Market Size and Forecast, By Drug Type
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Capecitabine Market
      • 7.5.8.1. Market Size and Forecast, By Indication
      • 7.5.8.2. Market Size and Forecast, By Drug Type
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Capecitabine Market
      • 7.5.9.1. Market Size and Forecast, By Indication
      • 7.5.9.2. Market Size and Forecast, By Drug Type
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. F. Hoffmann-La Roche Ltd.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Mylan N.V.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Teva Pharmaceutical Industries Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Sanofi
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Pfizer Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Dr. Reddy's Laboratories Ltd.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Novartis AG
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Bayer AG
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Eli Lilly And Company.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Merck And Co., Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments